样式: 排序: IF: - GO 导出 标记为已读
-
Lighting the way: recent developments and applications in molecular optogenetics Curr. Opin. Biotech. (IF 7.7) Pub Date : 2024-03-29 Anja Armbruster, Asim ME Mohamed, Hoang T Phan, Wilfried Weber
Molecular optogenetics utilizes genetically encoded, light-responsive protein switches to control the function of molecular processes. Over the last two years, there have been notable advances in the development of novel optogenetic switches, their utilization in elucidating intricate signaling pathways, and their progress toward practical applications in biotechnological processes, material sciences
-
Combining enzyme and metabolic engineering for microbial supply of therapeutic phytochemicals Curr. Opin. Biotech. (IF 7.7) Pub Date : 2024-03-19 Maxence Holtz, Carlos G Acevedo-Rocha, Michael K Jensen
-
Neutrophils, an emerging new therapeutic platform Curr. Opin. Biotech. (IF 7.7) Pub Date : 2024-03-14 Alejandra López-Arredondo, José A Cruz-Cardenas, Jorge A Cázares-Preciado, Nicholas E Timmins, Marion EG Brunck
Neutrophils possess unique characteristics that render them indispensable to health, and patients with irregular neutrophil counts or functions suffer from increased morbidity and mortality. As neutrophils are short-lived postmitotic cells, genetic aberrations cannot be corrected directly in neutrophils and must be targeted in their progenitors. Neutrophils are increasingly being contemplated for a
-
Biotechnological polyphosphate as an opportunity to contribute to the circularization of the phosphate economy Curr. Opin. Biotech. (IF 7.7) Pub Date : 2024-03-13 Philipp Demling, Makarius Baier, Alexander Deitert, Jana Fees, Lars M Blank
Polyphosphates, chains of polymerized phosphate subunits, are used as food additives for various applications such as conservation, water retention, and pH buffering. Currently, the value chain of phosphates is linear, based on mining fossil phosphate rock, which is anticipated to be depleted in a few hundred years. With no replacement available, a transition to a circular phosphate economy, to which
-
Can biotechnology lead the way toward a sustainable pharmaceutical industry? Curr. Opin. Biotech. (IF 7.7) Pub Date : 2024-03-11 Deniz Etit, Samir Meramo, Ólafur Ögmundarson, Michael K Jensen, Sumesh Sukumara
The impact-intensive and rapidly growing pharmaceutical industry must ensure its sustainability. This study reveals that environmental sustainability assessments have been conducted for only around 0.2% of pharmaceuticals, environmental impacts have significant variations among the assessed products, and different impact categories have not been consistently studied. Highly varied impacts require assessing
-
Emerging trends in production of plant natural products and new-to-nature biopharmaceuticals in yeast Curr. Opin. Biotech. (IF 7.7) Pub Date : 2024-03-06 Thomas Perrot, Jillian Marc, Enzo Lezin, Nicolas Papon, Sébastien Besseau, Vincent Courdavault
Natural products represent an inestimable source of valuable compounds for human health. Notably, those produced by plants remain challenging to access due to their low production. Potential shortages of plant-derived biopharmaceuticals caused by climate change or pandemics also regularly tense the market trends. Thus, biotechnological alternatives of supply based on synthetic biology have emerged
-
Metabolic engineering and fermentation of microorganisms for carotenoids production Curr. Opin. Biotech. (IF 7.7) Pub Date : 2024-03-05 Hyunmin Eun, Sang Yup Lee
Carotenoids are natural pigments that exhibit a wide range of red, orange, and yellow colors and are extensively used in the food, nutraceuticals, cosmetics, and aquaculture industries. While advances in systems metabolic engineering have established a foundation for constructing carotenoid-producing microbial cell factories at a laboratory scale, translating these technologies to industrial scales
-
Evaluating functionalities of food components by a model simulating human intestinal microbiota constructed at Kobe University Curr. Opin. Biotech. (IF 7.7) Pub Date : 2024-03-05 Ro Osawa, Itsuko Fukuda, Yasuhito Shirai
In this era of pandemics, reducing the risk of lifestyle-related diseases (LRD) by functional foods is of paramount importance. The conventional process of functional food development almost invariably involves , animal, and human intervention trials, but differences in intestinal environments between humans and experimental animals make it difficult to develop functional foods that are truly effective
-
Microbial synthesis of terpenoids for human nutrition — an emerging field with high business potential Curr. Opin. Biotech. (IF 7.7) Pub Date : 2024-03-05 Jules Beekwilder, Florence M Schempp, Matthew Q Styles, Oskar Zelder
Because of their complicated biosynthesis and hydrophobic nature, fermentative production of terpenoids did not play a significant role on a commercial scale until a few years ago. Driven by technological progress in metabolic engineering and process biotechnology, terpene-based food ingredients such as flavors, sweeteners, and vitamins produced by fermentation have now become viable and commercially
-
Advances in mass spectrometry-enabled multiomics at single-cell resolution Curr. Opin. Biotech. (IF 7.7) Pub Date : 2024-03-02 Rashmi Kumar, Kevin J Zemaitis, James M Fulcher, Ljiljana Paša-Tolić
Biological organisms are multifaceted, intricate systems where slight perturbations can result in extensive changes in gene expression, protein abundance and/or activity, and metabolic flux. These changes occur at different timescales, spatially across cells of heterogeneous origins, and within single-cells. Hence, multimodal measurements at the smallest biological scales are necessary to capture dynamic
-
Engineering metalloproteinase inhibitors: tissue inhibitors of metalloproteinases or antibodies, that is the question Curr. Opin. Biotech. (IF 7.7) Pub Date : 2024-03-01 Masoud Kalantar, Gregory A Hilpert, Ethan R Mosca, Maryam Raeeszadeh-Sarmazdeh
Targeting metalloproteinases (MPs) has been the center of attention for developing therapeutics due to their contribution to a wide range of diseases, including cancer, cardiovascular, neurodegenerative disease, and preterm labor. Protein-based MP inhibitors offer higher stability and selectivity, which is critical for developing efficient therapeutics with low off-target effects. Tissue inhibitors
-
Droplet-based microfluidics and enzyme evolution Curr. Opin. Biotech. (IF 7.7) Pub Date : 2024-03-01 Ankit Jain, Stavros Stavrakis, Andrew deMello
Enzymes are widely used as catalysts in the chemical and pharmaceutical industries. While successful in many situations, they must usually be adapted to operate efficiently under nonnatural conditions. Enzyme engineering allows the creation of novel enzymes that are stable at elevated temperatures or have higher activities and selectivities. Current enzyme engineering techniques require the production
-
Innovations and trends in antibody repertoire analysis Curr. Opin. Biotech. (IF 7.7) Pub Date : 2024-03-01 Douglas R Townsend, Dalton M Towers, Jason J Lavinder, Gregory C Ippolito
Monoclonal antibodies have revolutionized the treatment of human diseases, which has made them the fastest-growing class of therapeutics, with global sales expected to reach $346.6 billion USD by 2028. Advances in antibody engineering and development have led to the creation of increasingly sophisticated antibody-based therapeutics (e.g. bispecific antibodies and chimeric antigen receptor T cells)
-
Biobased de novo synthesis, upcycling, and recycling — the heartbeat toward a green and sustainable polyethylene terephthalate industry Curr. Opin. Biotech. (IF 7.7) Pub Date : 2024-02-29 Fabia Weiland, Michael Kohlstedt, Christoph Wittmann
-
Harnessing biocatalysis to achieve selective functional group interconversion of monomers Curr. Opin. Biotech. (IF 7.7) Pub Date : 2024-02-27 Madan R Gopal, Aditya M Kunjapur
-
Mineralized collagen scaffolds for regenerative engineering applications Curr. Opin. Biotech. (IF 7.7) Pub Date : 2024-02-24 Vasiliki Kolliopoulos, Brendan AC Harley
Collagen is a primary constituent of the tissue extracellular matrix. As a result, collagen has been a common component of tissue engineering biomaterials, including those to promote bone regeneration or to investigate cell-material interactions in the context of bone homeostasis or disease. This review summarizes key considerations regarding current state-of-the-art design and use of collagen biomaterials
-
Precision fermentation for improving the quality, flavor, safety, and sustainability of foods Curr. Opin. Biotech. (IF 7.7) Pub Date : 2024-02-23 Karson Hilgendorf, Yirong Wang, Michael J Miller, Yong-Su Jin
-
Fruit beers, beers with or without a co-fermentation step with fruits Curr. Opin. Biotech. (IF 7.7) Pub Date : 2024-02-20 Alejandro P Croonenberghs, Dries Bongaerts, Arne Bouchez, Jonas De Roos, Luc De Vuyst
-
In situ characterization of the tumor microenvironment Curr. Opin. Biotech. (IF 7.7) Pub Date : 2024-02-20 Habib Sadeghirad, Vahid Yaghoubi Naei, Ken O’Byrne, Majid E Warkiani, Arutha Kulasinghe
-
Bridging the gender gap in autoimmunity with T-cell–targeted biomaterials Curr. Opin. Biotech. (IF 7.7) Pub Date : 2024-02-19 Aida López Ruiz, Eric D Slaughter, April M Kloxin, Catherine A Fromen
-
Single-cell omics analysis with genome-scale metabolic modeling Curr. Opin. Biotech. (IF 7.7) Pub Date : 2024-02-15 Yu Chen, Johan Gustafsson, Jingyu Yang, Jens Nielsen, Eduard J Kerkhoven
Single-cell technologies have been widely used in biological studies and generated a plethora of single-cell data to be interpreted. Due to the inclusion of the priori metabolic network knowledge as well as gene–protein–reaction associations, genome-scale metabolic models (GEMs) have been a powerful tool to integrate and thereby interpret various omics data mostly from bulk samples. Here, we first
-
Anti-inflammatory and immunomodulatory properties of polysaccharides in mushrooms Curr. Opin. Biotech. (IF 7.7) Pub Date : 2024-02-15 Masashi Mizuno, Ken-ichiro Minato
-
What’s new in single-cell proteomics Curr. Opin. Biotech. (IF 7.7) Pub Date : 2024-02-14 Thy Truong, Ryan T. Kelly
-
Engineering protein nanoparticles for drug delivery Curr. Opin. Biotech. (IF 7.7) Pub Date : 2024-02-13 Blake A Richards, Antonio G Goncalves, Millicent O Sullivan, Wilfred Chen
Protein nanoparticles offer a highly tunable platform for engineering multifunctional drug delivery vehicles that can improve drug efficacy and reduce off-target effects. While many protein nanoparticles have demonstrated the ability to tolerate genetic and posttranslational modifications for drug delivery applications, this review will focus on three protein nanoparticles of increasing size. Each
-
Green horizons: how plant synthetic biology can enable space exploration and drive on Earth sustainability Curr. Opin. Biotech. (IF 7.7) Pub Date : 2024-02-10 Matthew Fox Morgan, Jonathan Diab, Matthew Gilliham, Jenny C Mortimer
-
Overview on biotics development Curr. Opin. Biotech. (IF 7.7) Pub Date : 2024-02-09 Anne-Emmanuelle Roux, Philippe Langella, Rebeca Martin
-
Regulatory mechanisms underlying yeast chemical stress response and development of robust strains for bioproduction Curr. Opin. Biotech. (IF 7.7) Pub Date : 2024-02-07 Bing Yuan, Wei-Bin Wang, Ya-Ting Wang, Xin-Qing Zhao
-
Mass spectrometry imaging methods for visualizing tumor heterogeneity Curr. Opin. Biotech. (IF 7.7) Pub Date : 2024-02-07 Kyle D Duncan, Helena Pětrošová, Julian J Lum, David R Goodlett
-
Recent advances in prime editing technologies and their promises for therapeutic applications Curr. Opin. Biotech. (IF 7.7) Pub Date : 2024-02-07 Hongzhi Zeng, Tyler C Daniel, Ananya Lingineni, Kelly Chee, Komal Talloo, Xue Gao
Prime editing (PE) is a groundbreaking genome editing technology offering unparalleled precision in targeted genome modifications and has great potential for therapeutic applications. This review delves into the core principles of PE and emphasizes its advancements, applications, and prospects. We begin with a brief introduction to PE principles, followed by a detailed examination of recent improvements
-
Impact of hormesis to deepen our understanding of the mechanisms underlying the bioactivities of polyphenols Curr. Opin. Biotech. (IF 7.7) Pub Date : 2024-02-06 Akira Murakami
Cells, organs, and the whole body are continuously exposed to various types of stressors, including oxidative stress, protein denaturation, hypoxia, energy starvation, and pathogen insults. Hormesis is an adaptive phenomenon in which a stressor induces cellular stress responses at low or moderate doses, while catastrophic damage is manifested at high doses. Polyphenols, as xenobiotic phytochemicals
-
-
Bridging bench to body: ex vivo models to understand articular cartilage repair Curr. Opin. Biotech. (IF 7.7) Pub Date : 2024-02-01 Anna Trengove, Serena Duchi, Carmine Onofrillo, Dulani Sooriyaaratchi, Claudia Di Bella, Andrea J O’Connor
-
Corrigendum to: “Design, construction, and application of noncanonical redox cofactor infrastructures” [Curr Opin Biotechnol 84 (2023) 103019] Curr. Opin. Biotech. (IF 7.7) Pub Date : 2024-01-31 William B Black, Sean Perea, Han Li
Abstract not available
-
Extracellular vesicles as therapeutics for inflammation and infection Curr. Opin. Biotech. (IF 7.7) Pub Date : 2024-01-25 Daniel Levy, Talia J Solomon, Steven M Jay
-
Nonsterile microbial production of chemicals based on Halomonas spp Curr. Opin. Biotech. (IF 7.7) Pub Date : 2024-01-22 Jing Zhang, Xu Yan, Helen Park, Nigel S Scrutton, Tao Chen, Guo-Qiang Chen
The use of extremophile organisms such as Halomomas spp. can eliminate the need for fermentation sterilization, significantly reducing process costs. Microbial fermentation is considered a pivotal strategy to reduce reliance on fossil fuel resources; however, sustainable processes continue to incur higher costs than their chemical industry counterparts. Most organisms require equipment sterilization
-
Engineering bacteria for cancer immunotherapy Curr. Opin. Biotech. (IF 7.7) Pub Date : 2024-01-13 Jesse G Zalatan, Lorenzo Petrini, Roger Geiger
Bacterial therapeutics have emerged as promising delivery systems to target tumors. These engineered live therapeutics can be harnessed to modulate the tumor microenvironment or to deliver and selectively release therapeutic payloads to tumors. A major challenge is to deliver bacteria systemically without causing widespread inflammation, which is critical for the many tumors that are not accessible
-
Overcoming barriers to medium-chain fatty alcohol production Curr. Opin. Biotech. (IF 7.7) Pub Date : 2024-01-13 Yun Su, Anna M Mangus, William T Cordell, Brian F Pfleger
-
Designer protein compartments for microbial metabolic engineering Curr. Opin. Biotech. (IF 7.7) Pub Date : 2024-01-09 Zhen Fang, Ya-Jiao Zhu, Zhi-Gang Qian, Xiao-Xia Xia
Protein compartments are distinct structures assembled in living cells via self-assembly or phase separation of specific proteins. Significant efforts have been made to discover their molecular structures and formation mechanisms, as well as their fundamental roles in spatiotemporal control of cellular metabolism. Here, we review the design and construction of synthetic protein compartments for spatial
-
Resolving cellular dynamics using single-cell temporal transcriptomics Curr. Opin. Biotech. (IF 7.7) Pub Date : 2024-01-09 Yifei Liu, Kai Huang, Wanze Chen
-
Toward rapid and efficient utilization of nonconventional substrates by nonconventional yeast strains Curr. Opin. Biotech. (IF 7.7) Pub Date : 2024-01-03 Hyun Gi Koh, Sangdo Yook, Hyunjoon Oh, Christopher V Rao, Yong-Su Jin
-
Metabolomics-based development of bioproduction processes toward industrial-scale production Curr. Opin. Biotech. (IF 7.7) Pub Date : 2023-12-28 Kenya Tanaka, Takahiro Bamba, Akihiko Kondo, Tomohisa Hasunuma
-
Excite the unexcitable: engineering cells and redox signaling for targeted bioelectronic control Curr. Opin. Biotech. (IF 7.7) Pub Date : 2023-12-26 Sally Wang, Futoon O Aljirafi, Gregory F Payne, William E Bentley
-
Biological recognition and cellular trafficking of targeted RNA-lipid nanoparticles Curr. Opin. Biotech. (IF 7.7) Pub Date : 2023-12-27 Oscar Escalona-Rayo, Panagiota Papadopoulou, Bram Slütter, Alexander Kros
Lipid nanoparticles (LNPs) have unlocked the potential of ribonucleic acid (RNA) therapeutics and vaccines. Production and large-scale manufacturing methods for RNA-LNPs have been established and rapidly accelerate. Despite this, basic research on LNPs is still required, due to their high assembly complexity and fairly new development, including research on lipid organization, transfection optimization
-
Cell-free chemoenzymatic cascades with bio-based molecules Curr. Opin. Biotech. (IF 7.7) Pub Date : 2023-12-27 Henrik Terholsen, Sandy Schmidt
-
Defining the boundaries: challenges and advances in identifying cells in microscopy images Curr. Opin. Biotech. (IF 7.7) Pub Date : 2023-12-23 Nodar Gogoberidze, Beth A Cimini
-
Two in one: the emerging concept of bifunctional antibodies Curr. Opin. Biotech. (IF 7.7) Pub Date : 2023-12-23 Kaitlin Rhee, Xin Zhou
Therapeutic antibodies have become indispensable for treating a wide range of diseases, and their significance in drug discovery has expanded considerably over the past few decades. Bifunctional antibodies are now emerging as a promising new drug modality to address previously unmet needs in antibody therapeutics. Distinct from traditional antibodies that operate through an ‘occupancy-based’ inhibition
-
Computational cell–cell interaction technologies drive mechanistic and biomarker discovery in the tumor microenvironment Curr. Opin. Biotech. (IF 7.7) Pub Date : 2023-12-23 Avery Pong, Clarence K. Mah, Gene W. Yeo, Nathan E. Lewis
-
Beyond fluorescence: advances in computational label-free full specificity in 3D quantitative phase microscopy Curr. Opin. Biotech. (IF 7.7) Pub Date : 2023-12-23 Daniele Pirone, Vittorio Bianco, Lisa Miccio, Pasquale Memmolo, Demetri Psaltis, Pietro Ferraro
-
Breaking tolerance: autoantibodies can target protein posttranslational modifications Curr. Opin. Biotech. (IF 7.7) Pub Date : 2023-12-22 Kristin J Lastwika, Paul D Lampe
-
Editorial overview: Analytical Biotechnology: It's all about getting smaller Curr. Opin. Biotech. (IF 7.7) Pub Date : 2023-12-22 Alexander Grünberger, Janina Bahnemann, Christian Dusny
Abstract not available
-
Valorization of single-carbon chemicals by using carboligases as key enzymes Curr. Opin. Biotech. (IF 7.7) Pub Date : 2023-12-20 Huijin Cheon, Jun-Hong Kim, Jeong-Sun Kim, Jin-Byung Park
-
Recent advances in the biological depolymerization and upcycling of polyethylene terephthalate Curr. Opin. Biotech. (IF 7.7) Pub Date : 2023-12-20 Lita Amalia, Chia-Yu Chang, Steven S-S Wang, Yi-Chun Yeh, Shen-Long Tsai
-
Immune response to the components of lipid nanoparticles for ribonucleic acid therapeutics Curr. Opin. Biotech. (IF 7.7) Pub Date : 2023-12-19 Sunny P Chen, Anna K Blakney
-
N-acetyl-aspartate metabolism at the interface of cancer, immunity, and neurodegeneration Curr. Opin. Biotech. (IF 7.7) Pub Date : 2023-12-15 Nils Krause, Andre Wegner
-
Progress and challenges in the translation of cancer nanomedicines Curr. Opin. Biotech. (IF 7.7) Pub Date : 2023-12-14 Fan Tong, Yufan Wang, Huile Gao
With the booming development of nanotechnology, nanomedicines have made considerable progress in the pharmaceutical field. However, the number of nanodrugs approved for clinical treatment is very limited. The main obstacles stem from the complexity of nanomedicine composition, tumor heterogeneity, complexity and incomplete understanding of nanotumor interactions, uncontrollable scaling, high production
-
Next-generation biological vector platforms for in vivo delivery of genome editing agents Curr. Opin. Biotech. (IF 7.7) Pub Date : 2023-12-15 Delphine Leclerc, Michael D Siroky, Shannon M Miller
CRISPR-based genome editing holds promise for addressing genetic disease, infectious disease, and cancer and has rapidly advanced from primary research to clinical trials in recent years. However, the lack of safe and potent in vivo delivery methods for CRISPR components has limited most ongoing clinical trials to ex vivo gene therapy. Effective CRISPR in vivo genome editing necessitates an effective
-
Impact of protein coronas on nanoparticle interactions with tissues and targeted delivery Curr. Opin. Biotech. (IF 7.7) Pub Date : 2023-12-16 Wei-Chun Chou, Zhoumeng Lin
A major challenge in advancing nanoparticle (NP)-based delivery systems stems from the intricate interactions between NPs and biological systems. These interactions are largely determined by the formation of the NP–protein corona (PC), in which proteins spontaneously adsorb to the surface of NPs. The PC endows the NPs with a new biological identity, capable of altering the interactions of NPs with
-
Engineering Saccharomyces cerevisiae for application in integrated bioprocessing biorefineries Curr. Opin. Biotech. (IF 7.7) Pub Date : 2023-12-12 Letitia S Minnaar, Francois Kruger, Jordan Fortuin, Lazzlo J Hoffmeester, Riaan den Haan
-
Engineered methane biocatalysis: strategies to assimilate methane for chemical production Curr. Opin. Biotech. (IF 7.7) Pub Date : 2023-12-15 Nam Kyu Kang, Tin Hoang Trung Chau, Eun Yeol Lee
-
Applying artificial intelligence and computational modeling to nanomedicine Curr. Opin. Biotech. (IF 7.7) Pub Date : 2023-12-12 Sean Hamilton, Benjamin R Kingston
Achieving specific and targeted delivery of nanomedicines to diseased tissues is a major challenge. This is because the process of designing, formulating, testing, and selecting a nanoparticle delivery vehicle for a specific disease target is governed by complex multivariate interactions. Computational modeling and artificial intelligence are well-suited for analyzing and modeling large multivariate